Physician/Scientist. Head and Neck Oncologist (radiation). Interests in cancer genomics, immunotherapy & DNA repair. @MSKCancerCenter
New York, NY
Joined May 2009
- Tweets2.1K
- Following2K
- Followers2.3K
- Likes18.8K
Pinned Tweet
🥳🎆 Kicking of 2026 with our work showing intra-tumoral bacteria 🦠 affect outcomes of Radiotherapy + anti-PD-L1 now out in @NatureCancer with sister paper by @nataliesilvermd! Even when trials "fail" – we can learn from them! nature.com/articles/s43018-0…. -- w/ @GeneCollector, @imrtlee, @TylerAlban1, @DrHaddadRobert, the Pfizer team and more! (1/N)
Nadeem Riaz retweeted
I am thrilled to share that our work “Type I IFN promotes ILC2-to-ILC1 plasticity in pre-clinical radiation-induced lung injury” was published today in Nature Communications. I couldn’t be more proud of our team! @COH_RadOnc @NatureComms
nature.com/articles/s41467-0… – at Duarte, CA
Nadeem Riaz retweeted
Now in @JAMAOnc:
We report 5y outcomes post 30 Gy elective RT (total 70 Gy CCRT) for 276 pts w/ HPV-related OPC #hncsm at @MSKCancerCenter #radonc
LRC 97.0%
OS 90.8%
PFS 85.9%
DMFS 91.2%
@imrtlee @xrtGenomics @seanmmcbride @CJTsaiMDPhD @EChrisDee
👉 shorturl.at/liqpP
Nadeem Riaz retweeted
Well written review by @imrtlee @xrtGenomics et al and an easy read for the non-rad onc, contextualizing differences between the two phase III trials comparing IMRT to IMPT for oropharyngeal cancer. ascopubs.org/doi/full/10.120…
Nadeem Riaz retweeted
Incredibly proud of Sudarshan Ramanan @sramanan03, @George_Ashji, and team who led our newly published commentary in @JCO_ASCO!
A remarkable achievement and a testament to the team's leadership, intellectual curiosity, and hard work.
🔗 ascopubs.org/doi/10.1200/JCO…
Excited to share our latest paper in the Journal of Clinical Oncology. Grateful to my co-authors
@EChrisDee, @imrtlee, @seanmmcbride, @xrtGenomics, @george_ashji, Eric Sherman, Khoi Nguyen, and Danil Ratnikov
@MSKCancerCenter @MSK_RadOnc @JCO_ASCO
ascopubs.org/doi/10.1200/JCO…
Nadeem Riaz retweeted
A new study published in @CD_AACR suggests that age-based germline screening for pathogenic variants misses the majority of inherited cancer risk variants, compared with universal screening. Read more: aacr.org/about-the-aacr/news…
Nadeem Riaz retweeted
1/2 #RadRes2026
Now this was illuminating, amd entertaining 😅👍
Painter Debate: ☢️what is the value of mouse experiments in radiation science❓️
@DKirschMDPhD and @CancerConnector going at it with much bravado, and wit🔥🔥
And, in David's case, as expecteded, rock solid data☺️
Nadeem Riaz retweeted
Sean Pitroda, whose work has raised concerns about the Badscopal effect, shares a few words of wisdom at #ASTRO26. Including the importance of total metastatic ablation of all visible sites in case irradiation of one tumor signals another unirradiated to grow.
#radonc has gigantic oppurtunity to improve care in metastatic cancer. But we need to understand our impact on the biology more — great session by @jeremy_setton @Samuel_Bakhoum , @CJTsaiMDPhD , @SeanPitroda — trying to unravel how to move biology in this space into the clinic #astro26
#ASTRO26
Accela and the neo. Proud for @RadOncUH to be the first center in the world to enroll a patient on a trial with this amazing tech.
@DrAndrewLoblaw @alison_tree @ASTRO_org @AmarUKishan @cwspeers @DrewMoghanaki @freddyeescorcia @EvanThomas84 @EricTopol @montypal @neerajaiims @wandering_gu @PGrivasMDPhD @shilpaonc @TylerSbrt @DrChoueiri @piet_ost @sueyom @jamesbyu @NehaVapiwala @NRGonc @nytimes @washingtonpost @EricTopol @urotoday @SbrtSean
Nadeem Riaz retweeted
🌎👋@NRGonc #HN009 p16-neg #ASTRO26; Dr. Paul Harari @UWMadison
➡️Diff AE profiles b/w Q1 vs Q3
➡️6 mo LRF diff 5% (Q1 9.6% & Q3 4.6%; 95%CI 1.0-8.9) Longer FU needed.
@DanielMaMD @quyhnhi99 @imrtlee @JamesBatesMD
@JJCaudell @drlorenmell @seanmmcbride @xrtGenomics
@ASTRO_org
No difference in overall survival with protons vs photons in OPC! Great work by our APP Ying! @imrtlee @seanmmcbride @yaoyu @CJTsaiMDPhD #astro26 #hncsm #radonc
Nadeem Riaz retweeted
🦠💡Next up - TRINITY trial presented by Zachary Zumsteg at @CedarsSinai, investigating reduced dose/volume CRT after TORS with excellent 2-yr PFS.
#ASTRO26 @ASTRO_org
@xrtGenomics @DanielMaMD @RobertFerrisMD @drdavidpalma
Nadeem Riaz retweeted
🚨‼️Happening now - technology driven strategies for HNSCC.
First talk - @imrtlee on FMISO pooled analyses.
#ASTRO26
@ASTRO_org
@xrtGenomics @seanmmcbride @MSK_RadOnc
Nadeem Riaz retweeted
🔵 Phase 2 (n = 98)randomized trial of proton beam RT vs IMRT in postoperative unilateral #HeadAndNeckCancer
➡️ Clinician-graded grade ≥2 mucositis 7.4% vs 22.7% (P=.03), dysgeusia 9.3% vs 31.8% (P=.005).
🔗: oxford.ly/4Ay4H9V
@IMRTLee | @xrtGenomics | @EChrisDee
Most RT-drug combos bet on synergy. Yet synergy is rare (most combos only additive). We're chasing a bar most of oncology can't clear. Our phase 1s don't even measure it. ProjectOptimus for #RadOnc & our editorial in @IJROBP w/Gustav, Ezra & @imrtlee -
doi.org/10.1016/j.ijrobp.202…
Must listen and must read!!
See also accompanying commentary by Nadeem Riaz @xrtGenomics which should be out soon in @IJROBP
#RedJournal #radonc #radbio
@finn_corinne
@sueyom
Nadeem Riaz retweeted
🧵 1/10 The arc: POLAR - MDF – TIE
Pancreatic cancer is profoundly resistant to immune checkpoint inhibitors.
Yet, POLAR (pembrolizumab plus olaparib) trial showed that a subset of patients, especially with HRD (gBRCA2/1m or gPALB2m) tumors, can achieve remarkably durable control.
That led us to two questions:
#1 👆🏼what makes these tumors immunogenic?
#2 ✌️what makes that immunity actually work?
👑 #2. POLAR TIE @biorxivpreprint
biorxiv.org/content/10.64898…
#1. MDF biorxiv.org/content/10.64898…
#0. POLAR @NatureMedicine nature.com/articles/s41591-0…
#cancer #immunotherapy #PancreaticCancer #ICI #BRCA #HRD #3episodes @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @ldiaz1971 @debschrag
@PanCAN @oncodaily @OncoDailyGI @OncoAlert @OncBrothers @brunolarvol – at Manhattan, NY
Nadeem Riaz retweeted
Starting a new thing at UNC with @BenjaminGVincen to figure out which tumor-specific pMHCs are actually on tumor cells & which vaccine platforms are more immunogenic.
Lots of long-read WGS/scRNA, targeted mass spec, tumor-specific TCRs coming your way in the near future
Nadeem Riaz retweeted
Excited to share our newest work in Nature Reviews Cancer, “Viral mimicry escape as a necessary feature of malignant transformation,” in which we propose that escaping viral mimicry is a new hallmark of cancer.
Nadeem Riaz retweeted
Congratulations to the team at @MSKCancerCenter/@MSK_RadOnc! Especially @imrtlee for the tireless advocacy for this effective, practice-changing strategy to safely cure oropharyngeal cancer with minimal side effects.
@seanmmcbride @xrtGenomics @ScottBratman @sueyom
🚨 The @FDA has granted “Breakthrough Therapy” designation to FMISO, a specialized imaging tracer that can help identify patients with #HPV-positive #throatcancer who may safely receive less-intensive radiation treatment.
“This has been an absolute game changer for treating certain people with throat cancers caused by the human papillomavirus or HPV,” says MSK radiation oncologist @imrtlee, who pioneered the approach.
Learn more: bit.ly/4AbDBoW
Nadeem Riaz retweeted
The bolus versus weekly cisplatin debate rages on, but fortunately more data dropped this past week with the publication of the ConCERT trial (Concurrent Chemotherapy and External Radiation Therapy) comparing bolus with weekly schedules.
Some thoughts on this trial and the cisplatin schedules below.
academic.oup.com/jnci/articl…
Nadeem Riaz retweeted
Major congrats to @imrtlee and @xrtGenomics (amongst others) on this wonderful news! The Ph3 is enrolling rapidly. This RCT has more practice changing potential than any in which I've had the good fortune to participate. #radonc #hnscc #medtwitter
onclive.com/view/fda-grants-…
